MOTS-c Reference

Educational, not medical advice reference for MOTS-c: Longevity, Metabolic; regulatory status, evidence posture, source review, and schedule not…

Plain English

What it is
MOTS-c is a tiny peptide that the body naturally makes inside its mitochondria, the parts of cells that turn food into energy. It is sold as a research-use chemical and is not approved by the FDA for use in people.
What people use it for
People in the peptide community talk about it for metabolic health, better blood sugar control, and so-called mitochondrial longevity. Researchers are still exploring it for aging and obesity, so every use is experimental and is not backed by a proven human plan.
What the science shows
Most of the real evidence comes from studies in mice, where it improved insulin sensitivity and lowered diet-driven obesity by switching on an energy-sensing pathway called AMPK. No large human trial has shown these benefits in people yet, so the longevity and exercise-mimic talk runs well ahead of the human data.
The catch
It is banned in sport at all times by the World Anti-Doping Agency as a metabolic modulator, so a tested athlete can fail a drug test from it. It is not FDA-approved, and a US advisory committee is set to review in July 2026 whether pharmacies should be allowed to compound it.

Reference summary

The foundational program is Lee 2015 Cell Metabolism (PMID 25738459, 'The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance'), which characterized AMPK activation and folate one-carbon metabolism inhibition (de novo purine synthesis) as the proposed mechanism, with insulin-sensitivity improvement and glucose-uptake increases in skeletal muscle in diet-induced obese mice. Cross-sectional human plasma work shows MOTS-c circulates at low picogram-per-milliliter concentrations, declines with age (about 11 percent lower in middle-aged and about 21 percent lower in older men versus young men), and rises acutely after exercise in some cohorts. No large randomized human outcome trial of exogenous MOTS-c administration has read out.

Regulatory and posture

Categories
Longevity, Metabolic
Aliases
Mitochondrial open reading frame of 12S rRNA type-c, Mitochondrial-derived peptide, MOTSc
Evidence posture
translational - Reproducible rodent metabolic-homeostasis program (Lee 2015) and credible cross-sectional human plasma biology, but no published large randomized human outcome trial of exogenous MOTS-c administration on an obesity, insulin-resistance, or longevity endpoint. Community 'mitochondrial longevity' or 'exercise mimetic' framing outruns the human data.
Regulatory status
No FDA-approved MOTS-c drug label. MOTS-c is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR) encoded within a short open reading frame embedded in the mitochondrial 12S rRNA (MT-RNR1) gene. It is the best-characterized member of the mitochondrial-derived peptide (MDP) family, which also includes humanin (encoded in 16S rRNA / MT-RNR2) and the small humanin-like peptides SHLP1 through SHLP6 (also 16S rRNA). FDA's bulk-substances posture flags peptides marketed for research use. The Pharmacy Compounding Advisory Committee reviewed MOTS-c on July 23, 2026 (Federal Register notice 2026-07361, docket FDA-2025-N-6895) alongside BPC-157, TB-500, and KPV, and narrowly recommended it for inclusion on the 503A Bulks List, against FDA's own reviewers. That recommendation does not bind FDA, and MOTS-c is not on the 503A Bulks List and is not permitted for 503A compounding unless and until FDA completes rulemaking. WADA prohibits MOTS-c at all times under category S4.4 (metabolic modulators).
Content review status
research reference

Selected public sources

Related tools

For research and educational purposes only. Not medical advice.